Study of GS-0415 and How It Works in People With HIV
Eligible age
18–65 yrs
Accepts
All genders
Locations
11 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and intravenous (IV) GS-0415 in people with HIV-1 (PWH) on antiretroviral treatment. The primary objectives of this study are to evaluate the safety and tolerability of escalating, single and multiple subcutaneous (SC) and intravenous (IV) doses of GS-0415, administered in PWH who are virologically suppressed on antiretroviral therapy (ART) and to evaluate the pharmacokinetics (PK) of GS-0415.
Sponsor: Gilead Sciences
Where it's recruiting
Los Angeles
Washington D.C.
Miami Lakes · West Palm Beach
Atlanta · Columbus
Indianapolis
Boston
Las Vegas
Newark
The Bronx
Durham · Winston-Salem
Cincinnati · Columbus
Source: ClinicalTrials.gov · NCT07719491 · last updated 2026-09-23